



Eidgenössische Technische Hochschule Zürich
Swiss Federal Institute of Technology Zurich

ETH Zurich to celebrate its 150th anniversary in 2005

Symposium on perspectives in drug discovery, development and clinical aspects in the postgenomic era

Drugs in the Postgenomic Era: Discovery, Development and Clinical Aspects

Date and time: March 16, 2005, 09:00 to 16:45

Venue

Hönggerberg Campus, ETH Zürich, Wolfgang-Pauli-Strasse 10
Building HCI, Auditorium G3, www.ethz.ch/about/location/ethhoengg

Scope

Exploitation of the large database of DNA sequences sampled from the human genome has become a hallmark in drug discovery and development. Although the promise of genomics may be more cumbersome to fulfill than initially hoped, it is now firmly established that the way to identify new potential drug targets has undergone a fundamental change. So have the strategies to discover lead compounds and develop the related therapeutics. Even more so, gene profiling has become a beneficial tool to come up with individualized therapies for distinct populations of patients in order to improve clinical efficacy, and lower side effects and toxicity. To explain this context to a transdisciplinary audience interested in the future perspectives of drug discovery, development and clinical aspects in the postgenomic era, we have invited six distinguished experts in the field from both academia and the pharmaceutical industry.

Attendance

The Symposium is open to the interested public. We particularly invite an audience involved or interested in life sciences aspects in fundamental, preclinical and clinical drug research and development. Attendance and refreshments are free of charge. There is no registration necessary. For additional information regarding the Symposium please contact our website: <http://www.hci-feier.ethz.ch>

Program

- 09:00 Welcome
- 09:15 *Dr. Dalia Cohen*, Novartis Institutes for Biomedical Research, Cambridge, MA (USA) “*From Genome to Therapy*”
- 10:00 *Professor René Bernards*, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam (The Netherlands) “*Identification of Novel Drug Targets Using RNA Interference*”
- 10:45 Break and Posters
- 11:15 *Professor Wolfgang Sadée*, College of Medicine and Public Health, Ohio State University, Columbus, OH (USA) “*Pharmacogenetics of Gene Regulation and mRNA Processing: An Abundant Source of Phenotypic Variability*”
- 12:00 Lunch Break and Posters
- 14:00 *Professor William E. Evans*, St. Jude Children’s Research Hospital and University of Tennessee Colleges of Pharmacy and Medicine, Memphis, TN (USA) “*Pharmacogenomics: Acute Lymphoblastic Leukemia (ALL) as a Cancer Paradigm*”
- 14:45 *Professor Michael Detmar*, ETH Zürich (Switzerland) “*The Vascular System - a New Target for the Treatment of Cancer and Inflammation*”
- 15:30 Break and Posters
- 16:00 *Professor Hans-Joachim Böhm*, Head Discovery Technologies, F. Hoffmann-La Roche Ltd., Basel (Switzerland) “*The Role of Chemical Genomics in Current Drug Discovery Research*”
- 16:45 Concluding Remarks

Contact

Phone: +41 44 633 73 11
christina.brun@pharma.ethz.ch